Trial intelligence / Profile preview

Combretastatin A-4 phosphate plus paclitaxel and carboplatin versus paclitaxel and carboplatin in anaplastic thyroid carcinoma

2007-002846-38Phase 2Terminated

Sponsor: OXiGENE, Inc.
Start: Jul 2007
Modality: DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial in anaplastic thyroid cancer (ATC) comparing Combretastatin A-4 phosphate + paclitaxel + carboplatin with Paclitaxel + carboplatin (2 arms). Primary endpoint: Overall survival. Started Jul 2007; status: terminated.

Drugs

fosbretabulinpaclitaxelcarboplatin

Conditions

anaplastic thyroid cancer (ATC)

Beyond the preview

Go deeper on 2007-002846-38.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2007-002846-38.